Compare Freeport-McMoRan Inc (FCX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Repligen Corporation Common Stock — how do they compare? Freeport-McMoRan Inc trades at $69.13 (market cap $104.00B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Freeport-McMoRan Inc is far larger — about 9.3× Repligen Corporation Common Stock's market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 70 Days and Repligen Corporation Common Stock for 0 Days on average.
| FCX | RGEN | |
|---|---|---|
Market Cap | $104.00B | $11.14B |
Volume | 7,316,762 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $194.57 |
52-Week Low | $38.65 | $102.87 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $110.28B | $11.02B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, down 5.01% today, but maintains strong technical momentum with bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Copper demand fundamentals remain robust, driven by AI infrastructure needs, while FCX's expansion projects position it for growth. Analyst consensus remains strongly bullish with a $73.27 price target.
FCX presents a compelling investment case with strong copper demand tailwinds and consistent earnings outperformance. However, rising production costs and a high P/E ratio of 35.5 warrant caution. The stock offers exposure to copper's structural deficit while carrying execution risks from expansion projects and commodity price volatility.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
